Category: Health

Categories
Health

A ‘Recreation Changer’ for Sufferers With Esophageal Most cancers

A ‘Game Changer’ for Patients With Esophageal Cancer

Chemotherapy has difficult side effects, and the radiation causes a burning sensation that makes it difficult to swallow. “The food won’t go down,” said Ms. Mordecai. “You just feel lazy.”

The next step is major surgery. A doctor removes most of the patient’s esophagus, with the tract going from the mouth to the stomach. He then grabs the stomach, pulls it up, and attaches it to a leftover esophageal stump.

The result is a stomach that is vertical rather than horizontal and that lacks the sphincter muscle that normally prevents stomach acid from leaking out. For the rest of their lives, patients can never lie flat – when they do, the contents of their stomach, including acid, flow down their throats. They can choke, cough, and aspirate.

Recovery is difficult and morbidity and mortality are high. But most patients do the surgery once they have weighed their options. Refusing treatment means giving up and letting the cancer close the esophagus so much that some cannot even swallow their own saliva, said Dr. Paul Helft, professor of surgery and ethicist at Indiana University School of Medicine.

The treatment is so long and harrowing that Dr. Often used to help educate medical students and other trainees about informed consent – how patients need to be fully informed before starting any given treatment. In particular, patients with esophageal cancer should be warned that they are likely to recur within the first year.

Ms. Mordecai said that her husband had an operation in late September 2008. By December 6th, he had untreatable metastases in his liver. Now, she said, the patients might have a glimmer of hope.

Dr. Ilson, who has spent his career developing therapies to help patients with esophageal cancer, said he did not expect this treatment to be successful: “We all become nihilistic after years of negative study.”

“This is really a milestone,” he added, and the drug “will set a new standard for care.”

Categories
Health

WHO warns of an increase in Covid instances and deaths: ‘We’re all struggling’

WHO warns of a rise in Covid cases and deaths: ‘We’re all struggling’

World Health Organization (WHO) Director General Tedros Adhanom Ghebreyesus attends a press conference after the Emergency Committee for Pneumonia Due to Novel Coronavirus 2019-nCoV attended a press conference in Geneva, Switzerland on January 22nd. 2020.

Christopher Black | WHO | Handout via REUTERS

The World Health Organization warned of a steady spike in Covid-19 cases and deaths in recent weeks and urged people on Wednesday to adhere to mask mandates and social distancing rules as the world enters a critical phase of the pandemic.

“We are in our second year of the pandemic. There is a lot of frustration and fatigue out there wanting this pandemic to be over, but as the transmission increases, it is going in the wrong direction,” said Dr. Maria Van Kerkhove, the WHO Technical Director of Covid-19, said during a Q&A at the organization’s headquarters in Geneva. “It’s far from over. We’re not talking about a handful of cases here and there. We’re still in the acute phase of the pandemic.”

The number of cases rose 14% worldwide last week – the sixth straight weekly increase – and the death toll rose for the third straight week, she said. Globally, there have been more than 128 million Covid-19 cases and 2.8 million deaths since the virus emerged just over a year ago, according to John Hopkins University.

The countries with the largest transmission leaps are India, the USA, Brazil, Turkey, Poland, Italy, Ukraine, the Philippines, Germany and Iran.

French President Emmanuel Macron on Wednesday ordered the country’s third national lockdown and said schools would close for three weeks as the country tries to fend off a third wave of infections that threatens to overflow hospitals.

“We will lose control if we don’t move now,” he said in a televised address to the nation.

The virus is “stronger, it’s faster” as new varieties emerge that are easier to spread and more deadly than the original wild strain of the virus, said Dr. Mike Ryan, WHO Emergency Program Director. “We all have problems” and fed up with restrictive bans, he said.

“It’s a turning point in the pandemic because the moment we have to stay on course with all of this, the numbers are rising and governments are turning back to restrictive measures,” he said.

Categories
Health

The C.D.C. and N.I.H. launch a fast, at-home testing initiative in Tennessee and North Carolina.

The C.D.C. and N.I.H. launch a rapid, at-home testing initiative in Tennessee and North Carolina.

The Centers for Disease Control and Prevention and the National Institutes of Health announced a new initiative on Wednesday to see if the frequent and widespread use of rapid coronavirus tests is slowing the spread of the virus.

The program will provide free antigen testing at home to everyone in two communities, Pitt County, NC, and Hamilton County, Tennessee, for free, bringing a total of 160,000 people to test for the coronavirus three times a week for a while a month.

“This is exactly what I and others have been calling for almost a year – widespread, accessible, rapid testing to contain transmission,” said Michael Mina, Harvard University epidemiologist who advocated rapid rapid testing at home programs.

He added, “It’s something anyone can do if they take 30 seconds out of the day three times a week to do the test.”

Antigen tests are cheaper and faster than PCR tests, which are the gold standard for diagnosing Covid-19, the disease caused by the virus. However, they are less sensitive and more prone to false negative results. Mathematical models have shown that if these tests are used frequently, they can still reduce the transmission of the virus.

The tests can help identify people who may not realize they are infectious and cause them to self-isolate before they can transmit the virus to others. Real world data is limited, however, and with virus cases still high across the country, testing is still essential, according to public health experts.

“We have all hypothesized that large-scale home testing could stop the chain of transmission of the virus and allow communities to discover many more cases,” said Bruce Tromberg, who heads the National Institute for Biomedical Imaging and Bioengineering and its rapid acceleration directs the diagnostic program that provides the tests for the initiative. “All mathematical models predict that. But this is an example from the real world, real life. “

Residents who choose to participate in the program can have the tests brought to their home or collect them from local distribution locations. An online tool guides participants through the testing process and helps them interpret their results. Residents can also volunteer to take surveys to see if frequent tests have changed their behavior, knowledge of Covid-19, or their minds about vaccination.

Researchers from the University of North Carolina and Duke University will compare the positivity, case, and hospitalization rates in these two communities with those in other similar communities that are not in the program.

A. David Paltiel, Professor of Health Policy and Management at the Yale School of Public Health, described the start of a real-world study of the effectiveness of rapid home screening as “simply good news.” However, he cautioned that the results need to be interpreted carefully, especially if residents who choose to participate in the initiative are not representative of the entire community.

“We know that self-selection tends to bring out the concerned and a disproportionate number of people who are already Covid-aware or Covid-conscientious,” he said.

“It will be great to see how it works when it’s in the hands of people who really care,” he added. However, he said the results may not be broadly applicable to screening programs that require participation, as may be the case with some workplace and school programs.

Categories
Health

Covid was third main reason for dying in U.S. in 2020, behind coronary heart illness and most cancers, CDC says

Covid was third leading cause of death in U.S. in 2020, behind heart disease and cancer, CDC says

The body of a deceased patient is considered a health care worker treating individuals infected with coronavirus disease (COVID-19) on December 30, 2020 at the United Memorial Medical Center in Houston, Texas, United States.

Callaghan O’Hare | Reuters

Coronavirus was the third leading cause of death in the United States in 2020, after heart disease and cancer, according to a new study by the U.S. Centers for Disease Control and Prevention.

More than 3.3 million deaths were reported in the US last year, up 16% from 2019. This is according to early data released Wednesday by the National Vital Statistics System, which provides annual mortality statistics based on death certificates investigates and reports.

The deadliest weeks of last year were at the start of the pandemic and then in the middle of the holiday flood in the weeks leading up to April 11, with 78,917 deaths, and December 26, when 80,656 people died, the CDC found.

According to the study published on Wednesday, Covid-19 was listed as the root cause of 345,323 deaths. More Americans died in the process than accidental injuries, strokes, chronic lower respiratory diseases, Alzheimer’s, diabetes, influenza and pneumonia, and kidney disease.

Only heart disease and cancer killed more people than Covid-19 in the US in 2020 – heart disease killed 690,882 people and cancer killed 598,932.

Covid-19 replaced suicide in the top 10 leading causes of death in the United States, the study found. Overall, the annual death rate rose nearly 16% year over year in 2020, the first time since 2017, according to the CDC.

The highest annual death rates were reported among men, people age 85 and over, and people who are not Hispanic Black and Native American and Alaskan native, according to the CDC.

However, if you just look at Covid-19, Hispanic and Native American and Alaskan Native Americans, as well as those aged 85 and over, were more likely to die of the disease compared to any other group. Men died more often from Covid-19 than women.

CDC director Dr. Rochelle Walensky said after the study was published the results should “act as a catalyst” for Americans to reduce the spread of the virus and get vaccinated when it is their turn to get vaccinated.

“I know this is not easy and so many of us are frustrated with the disruption this pandemic has had in our daily lives, but we can do this as a nation that works together,” Walensky said during a White House press conference Covid-19

The agency’s first results were released months ahead of schedule as “freshness has improved and there is an urgent need for updated quality data during the global COVID-19 pandemic,” the researchers wrote.

Typically, it takes researchers 11 months after the end of the calendar year to “investigate specific causes of death and process and review data”. The daily Covid deaths reported by the CDC, while current, may underestimate the actual number of deaths due to “incomplete or late reports”.

“Preliminary death estimates provide an early indication of shifts in mortality trends and can guide public health policies and actions aimed at reducing the number of deaths directly or indirectly linked to the COVID-19 pandemic “write the researchers.

Some have tried to sow doubts about the real number of Covid-19 deaths, claiming they may have been overstated. However, in a separate CDC study released Wednesday, the agency found that the death certificates accurately reflected the number of reported coronavirus deaths.

The agency checked death certificates listing Covid-19 and at least one other concurrent illness. The CDC found that Covid-19 was reported in 97% of deaths alongside another condition that the virus might have caused, such as pneumonia or respiratory failure, or that contributed significantly to its severity, such as diabetes or high blood pressure.

A small fraction of them – 2.5% of the certificates – documented conditions not currently associated with Covid-19, the CDC noted.

“These results support the accuracy of COVID-19 mortality monitoring in the US using official death certificates,” the researchers said.

Categories
Health

The Pfizer-BioNTech Vaccine Is Stated to Be Powerfully Protecting in Adolescents

The Pfizer-BioNTech Vaccine Is Said to Be Powerfully Protective in Adolescents

The Pfizer BioNTech coronavirus vaccine is extremely effective in adolescents ages 12 to 15, perhaps even more effective than it is in adults, the companies reported on Wednesday. No symptomatic infections were found in children who received the vaccine in a recent clinical study. The children showed strong antibody reactions and did not show any serious side effects.

The results, if persistent, could accelerate the return to normal for millions of American families. Depending on government approval, vaccinations for middle school, high school and elementary school children might start not long before the start of the next school year.

The companies announced the results in a press release that did not include detailed data from the study that had not yet been peer-reviewed or published in a scientific journal. Still, the news was praised and excited by experts.

“Oh my god, I’m so happy to see this – it’s amazing,” said Akiko Iwasaki, an immunologist at Yale University. If the vaccine performance was A-plus in adults, the results in children were A-plus-plus.

The good news comes even if the country sees a renewed surge in infections and health officials again urge Americans to follow precautions and get vaccinated. On Monday, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, said rising cases left her feeling of “impending doom” while President Biden urged state and local officials to reinstate mask mandates.

Vaccination efforts are accelerating across the country. By Tuesday, 29 percent of Americans had received at least one dose of a coronavirus vaccine, and 16 percent had been fully vaccinated, according to the CDC

But the country cannot hope to achieve herd immunity – the point where immunity becomes so widespread that the coronavirus is slowing its passage through the population – without vaccinating the youngest Americans as well, some experts say. Children under the age of 18 make up approximately 23 percent of the population in the United States.

“The sooner we can get vaccines against as many people as possible, regardless of their age, the sooner we will feel like we are ending this pandemic for good,” said Angela Rasmussen, a virologist at Georgetown University in Washington.

Data from Israel suggest that vaccination in adults alone can significantly reduce the number of cases. “However, in order to reach the herd immunity threshold in the long term, we need to vaccinate children,” she said.

The study included 2,260 adolescents aged 12 to 15 years. The children received two doses of the vaccine three weeks apart – the same amounts and the same schedule as for adults – or a placebo with salt water.

The researchers registered 18 cases of symptomatic coronavirus infection in the placebo group and none among the children who received the vaccine. However, the low number of infections makes it difficult to accurately determine the effectiveness of the vaccine in the general population, said Dr. Rasmussen.

“But obviously it looks good for the vaccine if there are no Covid cases among the vaccinated people,” she added.

The adolescents who received the vaccine produced, on average, many more antibodies than those aged 16-25 in a previous study. The children experienced the same minor side effects as older participants, although the companies refused to be more specific.

Updated

March 31, 2021, 9:45 a.m. ET

Dr. Iwasaki said she expected antibody levels in teenagers to be comparable to those in young adults. “But they get even better readings from the vaccines,” she said. “That is really unbelievable.”

She and other experts warned that the vaccine may be less effective in children and adults against some of the variants that have come into circulation in the United States.

Pfizer and BioNTech started a clinical trial of the vaccine in children under the age of 12 just last week, and started vaccinating children ages 5 to 11. Scientists at the company plan to test the vaccine in even younger children ages 2 to 5 next week, followed by trials in children ages 6 months to 2 years.

Results from this three-phase study are expected in the second half of the year, and the companies hope to make the vaccine available to children under the age of 12 early next year.

“We share the urgency to expand the use of our vaccine to wider populations and are encouraged by data from clinical trials in adolescents 12-15 years of age,” said Albert Bourla, Pfizer chairman and CEO, in a statement.

Moderna has also tested its vaccine in children. Results of a study in adolescents aged 12 to 17 years are expected in the next few weeks and in children aged 6 months to 12 years in the second half of this year.

AstraZeneca started testing its vaccine in children 6 months and older last month, and Johnson & Johnson has announced that it will wait for the results of studies in older children before testing the vaccine in children under the age of 12.

Some parents have stated that they are reluctant to immunize their children because the risk of the virus is low. Children account for less than 1 percent of deaths from Covid-19, but about 2 percent of children with the disease require hospital care.

The new results may not affect all of these parents, but they can reassure parents who have been wary of vaccines, said Jennifer Nuzzo, an epidemiologist at the Johns Hopkins Center for Health Security.

“While I don’t think we have to wait for the children to be vaccinated to fully reopen schools, the ability to vaccinate children can help some families feel more secure when they return to school,” said they.

Pfizer and BioNTech plan to apply to the Food and Drug Administration for an emergency approval change for their vaccine in hopes of starting vaccinating older children before the start of the next school year. The companies also plan to submit their data for review and publication in a scientific journal.

You will monitor participants for two years after the second dose to assess the long-term safety and effectiveness of the vaccine. Vaccine side effects usually appear within the first six weeks, said Dr. Kristin Oliver, pediatrician and vaccine expert at Mount Sinai Hospital in New York. “Even so, it is good to know that security surveillance is continuing,” she said.

The CDC recommends that people do not receive any other vaccines for two weeks before and after receiving the two doses of the coronavirus vaccine.

But kids are getting more vaccines than ever before in the few weeks leading up to the school year, according to Dr. Oliver. Therefore, pediatricians and parents should try to get these other vaccinations earlier than usual.

The coronavirus vaccines should ideally be given by pediatricians with extensive experience immunizing children, added Dr. Oliver added. “Now is the time to plan how this rollout will take place in this age group,” she said.

Categories
Health

Pfizer says shot is 100% efficient in children ages 12 to 15

Pfizer says shot is 100% effective in kids ages 12 to 15

A nurse, Cindy Mendez, wearing a protective mask, holds a syringe containing a dose of Pfizer-BioNTech COVID-19 vaccine during the coronavirus disease (COVID-19) pandemic at NYC Health + Hospitals Harlem Hospital in the Manhattan neighborhood of New York City. New York, February 25, 2021.

Jeenah Moon | Reuters

Pfizer said on Wednesday that its Covid-19 vaccine was 100% effective in a study in adolescents ages 12-15.

Albert Bourla, CEO of Pfizer, said the company hoped to submit the new data on the vaccine, which was being developed in partnership with German drug maker BioNTech, “as soon as possible” to the Food and Drug Administration and other regulatory agencies that children in the age group can get vaccinated before the next school year.

“We share the urgency to expand our vaccine approval to younger populations and are encouraged by clinical trial data from adolescents 12-15 years of age,” Bourla said in a press release.

The study enrolled 2,260 participants in the United States. 18 confirmed Covid-19 infections were observed in the placebo group and no confirmed infections were observed in the group that received the vaccine, the company said. This resulted in a vaccine effectiveness of 100%. The shot is also well tolerated, with side effects generally the same as in adults.

The company also said the vaccine produced a “robust” antibody response in children that outperformed that in a previous study of 16-25 year olds.

Vaccinating children is critical to ending the pandemic, say public health officials and infectious disease experts. The nation is unlikely to achieve herd immunity – if enough people in a given community have antibodies to a given disease – until children can be vaccinated, experts say.

According to the government, children make up around 20% of the US population. According to experts, between 70% and 85% of the US population must be vaccinated against Covid to achieve herd immunity and some adults may refuse to get the shots.

Dr. Scott Gottlieb, a former FDA commissioner, said he expected it would take the U.S. agency about a month to review the new data. If the FDA process goes well, the vaccine could be available to children between the ages of 12 and 15 by the fall, he told CNBC’s Squawk Box.

Isaac Bogoch, an infectious disease specialist who served on various data and security monitoring bodies, described the results as “wonderful news”. This is a “big step forward” in protecting more people from the virus and making schools safer for children.

“We are talking about improving the safety of youth activities such as youth sports and art, as well as after-school activities for youth,” he said.

Pfizer’s vaccine has already been approved for use in the United States in people aged 16 and over. Clinical studies testing the vaccine in children whose immune systems may react differently than adults had yet to be completed.

The Chief Medical Officer of the White House, Dr. Anthony Fauci, speaking to a House committee earlier this month, said the U.S. could vaccinate older children against Covid-19 starting this fall, while elementary school-age children may get their shots early next year.

Moderna, which also has a US-approved vaccine, announced on March 16 that it has started testing its shot in children under the age of 12. Moderna started a study in December testing children ages 12-17.

Johnson & Johnson plans to test its single-shot vaccine in infants and even newborns after it was first tested in older children, according to the New York Times.

Pfizer announced last week that it had started a clinical trial testing its Covid-19 vaccine in healthy children aged 6 months to 11 years.

In the first phase of this study, the company will determine the preferred dosage level for three age groups – between 6 months and 2 years, 2 and 5 years, and between 5 and 11 years. The children will initially receive a dose of 10 micrograms of the vaccine before gradually moving to higher doses, according to the company. Participants also have the option of ingesting 3 micrograms doses.

Pfizer said Wednesday it plans to apply to the FDA for an amendment to its current emergency approval to include adolescents ages 12-15. All participants in the study will be monitored for two more years after their second dose, the company said.

Pfizer and BioNTech plan to submit the data for scientific review.

Categories
Health

Extra Looking forward to Covid Vaccine however Skeptics Stay, U.S. Ballot Says

More Eager for Covid Vaccine but Skeptics Remain, U.S. Poll Says

As eligibility to get the Covid-19 vaccination rapidly expanded to all adults in many states over the next month, a new survey shows that the number of Americans, especially black adults, who want to be vaccinated continues to grow. However, it has also been found that skepticism about vaccines persists, especially among Republicans and white Evangelical Christians, an issue that the Biden government has identified as an obstacle to achieving herd immunity and returning to normal life.

According to the latest monthly survey by the Kaiser Family Foundation, around 61 percent of adults have either received their first dose or are excited about one, up from 47 percent in January.

The shift was most noticeable among black Americans, some of whom were hesitant before but also had access problems. Since February, 14 percent more black adults said they wanted or had already received the vaccine. Overall, black adults, who have also received violent advertising campaigns from celebrities, local black doctors, clergy and public health officials, now want the vaccine in numbers almost comparable to other leading populations: 55 percent compared with 61 percent for Latinos and 64 percent for whites.

The Biden government has made justice a focus of its pandemic response, adding mass vaccination centers in several underserved communities. In early March, a New York Times analysis of state-reported race and ethnicity information found that vaccination rates for blacks in the United States were half that for whites and the gap was even greater for Hispanic Americans.

Dr. Reed Tuckson, founder of the Black Coalition Against Covid, welcomed the rising adoption rates but noted that practical issues still stand in the way of inclusion.

“The data and our anecdotal feedback encourage and support the need for equitable distribution and easily accessible vaccination sites run by trustworthy organizations,” he said. “The system has to support these decisions by doing the right thing to do the simple thing.”

Overall, the survey showed that the so-called waiting group – people who have not yet made a decision – is shrinking accordingly, now at 17 percent compared to 31 percent in January. The seven-day average of vaccines administered hit 2.77 million on Tuesday, an increase from the pace of the previous week. This is based on data reported by the Centers for Disease Control and Prevention.

The survey was conducted March 15-22 among a random sample of 1,862 adults.

Despite the progress, one in five adults (20 percent) said they would either definitely refuse the shot or would only be vaccinated if necessary for their job or school. A number of employers and institutions are considering making such a requirement. Last week, Rutgers University became the first major academic institution to require students to receive the vaccine this fall (with exceptions for medical or religious reasons).

The people most likely to speak out against vaccination identify themselves as Republicans (29 percent) or white Evangelical Christians (28 percent). In contrast, only 10 percent of black adults said they definitely wouldn’t get it.

According to the Kaiser poll and other polls, Republicans have changed little in their views on vaccine acceptance in recent months, despite being more open last fall, ahead of the November presidential election. The party-political divide between the Covid-19 shots is wide. Only 46 percent of Republicans say they received or intended to receive at least one shot, compared to 79 percent of Democrats.

No group is monolithic in their reasons for rejecting or accepting the vaccines. Those who are skeptical say they generally distrust the government and are concerned about the speed of vaccine development. Much of the online misinformation clings to a fast-spreading myth – that tracker microchips are embedded in the recordings.

For rural residents, access to the vaccine is so problematic that they simply don’t see the logistics and travel time involved as worth it.

With so many reasons cited for avoiding the vaccine, it can be difficult to get messages across to improve vaccine confidence. However, the most recent Kaiser report identified a few approaches that appear to be successful in getting people to think about the shots.

At least two-thirds of the so-called wait-and-see group said they would be convinced by the message that the vaccines are “almost 100 percent effective in preventing hospital stays and the death of Covid-19”. Other strong messages included information that the new vaccines are based on 20 year old technology, that the vaccine trials have involved a wide variety of candidates, and that the vaccines are free.

The survey also found that many people who hesitate would be open to certain incentives. With the country opening up and the return of work on the ground, the employer’s role in vaccination is becoming increasingly important. A quarter of those who hesitate and have a job said they would get the shot if their employer arranged for a workplace vaccination. Almost as many would agree if their employers gave them financial incentives between $ 50 and $ 200.

Overall, the strong growth in adults who have either received a dose of the vaccine or who are inclined to receive it is most likely due to their increased familiarity with the term. Surveys show that as they get to know more friends and relatives who got the shot, it is easier for them to imagine getting it themselves.

Categories
Health

U.S. joins 13 different nations in criticizing WHO’s China Covid report

U.S. joins 13 other nations in criticizing WHO's China Covid report

This photo taken on Feb. 17, 2020 shows medical workers working at an exhibition center that has been converted into a hospital in Wuhan, central China’s Hubei Province.

STR | AFP via Getty Images

WASHINGTON – The United States on Tuesday signed a joint statement with 13 other nations criticizing the World Health Organization’s long-awaited report on the origins of Covid-19.

In a joint statement, the governments of Australia, Canada, the Czech Republic, Denmark, Estonia, Israel, Japan, Latvia, Lithuania, Norway, South Korea, Slovenia, the United Kingdom and the United States wrote that the report “has been significantly delayed and there was no access to complete original data and samples. “

“In the event of a major outbreak of an unknown pandemic pathogen, rapid, independent, expert-led and unhindered origin assessment is critical to better prepare our employees, our public health facilities, our industries and our governments for a successful response to it Outbreak and prevent future pandemics, “the joint statement said.

“In the future, WHO and all Member States must reassign themselves to access, transparency and timeliness,” the group added.

The WHO’s 120-page report, published Tuesday and produced by a team of international scientists, helped improve the scientific community’s understanding of the deadly virus that was conquering the globe, but it fell short of a full assessment back.

“We have not yet found the source of the virus and we must continue to follow science and leave no stone unturned,” said WHO Director General Tedros Adhanom Ghebreyesus during a press conference on Tuesday.

“Finding the source of a virus takes time and we owe it to the world to find the source so we can take action together to reduce the risk of its recurrence. No single research trip can provide all the answers,” he added .

At the White House, press secretary Jen Psaki told reporters that the Biden administration is still examining the WHO report, adding that the results are “partial and incomplete”.

“The report lacks critical data, information and access. It presents a partial and incomplete picture,” said Psaki. “There is a second phase in this process that we believe should be led by international and independent experts. They should have full access to data,” she added.

Psaki criticized Beijing’s lack of transparency when asked about China’s participation in the WHO report, which was attended by at least 17 experts.

“Well, they weren’t transparent. They didn’t provide any underlying data. That is certainly not a cooperation,” she said.

Categories
Health

Bloomberg Staff Get Entry to Hospital’s Vaccine Slots

Bloomberg Employees Get Access to Hospital’s Vaccine Slots

NYU Langone Health, a major New York City hospital system, has put aside Covid-19 vaccination shots for employees of Bloomberg LP, billionaire Michael R. Bloomberg’s financial data and media company.

Bloomberg employees were informed of the agreement in an internal memo on February 16. On Tuesday, when adults aged 30 and over were eligible for vaccination in New York, Bloomberg Human Resources Director Ken Cooper sent a second email to employees on the subject with the subject “* URGENT * Covid-19 Vaccines in New York”.

“NYU Langone has informed us that they are able to provide limited quantities of vaccines to Bloomberg employees who meet the approval requirements on a weekly basis,” Cooper wrote in the email received from the New York Times.

In the email on Tuesday, employees were informed that they would be sent registration instructions after filing a ticket in the company’s financial terminal system. The memo added that only Bloomberg employees were eligible under the plan, not their loved ones.

“Given the complexity of vaccine delivery and distribution, we continue to encourage you to do whatever you can to make an appointment yourself if you are eligible to receive the vaccine,” the email said. “You may find these appointments come in sooner than those made available through NYU.”

A Bloomberg spokesman declined to comment.

Mr Bloomberg has donated billions of dollars to the environment, education, public health, and other causes, including more than $ 3 billion in gifts to his alma mater, Johns Hopkins University.

His philanthropic arm has given New York University at least two gifts. The university’s Robert F. Wagner Graduate School of Public Service announced on March 2 that it would receive a $ 25 million donation from Bloomberg Philanthropies. The gift was made for a scholarship on behalf of Mr. Bloomberg’s daughter Georgina and his mother Charlotte. In 2017, Mr Bloomberg’s philanthropic arm donated nearly $ 6 million to set up an environmental law center at New York University School of Law.

NYU Langone Health has “formal corporate partnerships with organizations, school districts and communities that we are the preferred providers offering corporate wellness programs and facilitating access to our services,” a hospital system spokeswoman said in a statement. “Through this partnership, we have helped secure vaccines for Bloomberg employees, who are our patients, in accordance with New York State guidelines.”

“Philanthropy is not tied to NYU Langone’s vaccination programs,” added the spokeswoman. Commenting on Mr. Bloomberg’s March 2 donation, she said, “It is important to note that the gift went to NYU’s Wagner Graduate School. It wasn’t done to NYU Langone Health or NYU Grossman School of Medicine. It was completely independent of our institution. “

New York residents over 30 qualified for the vaccine Tuesday, resulting in a rush to book appointments.

Mr Bloomberg has told his staff that he expects them to return to the office after vaccination. “As soon as vaccines are available, we expect people to use the security they provide and return to the office,” he wrote in a February 2 memo reported by Business Insider. “Any questions? I’m at my desk.”

Categories
Health

Research exhibits promising immune response towards variants

Study shows promising immune response against variants

Scientists at the Mirimus Laboratory prepare to test COVID-19 samples from recovered patients on April 8, 2020 in Brooklyn, New York.

Mischa Friedman | Getty Images

One type of T cell responsible for destroying cells infected with viruses was able to detect three variants of Covid-19 in a small US study, a promising sign that vaccines should continue to protect against new, emerging strains researchers at the National Institute of Allergy and Infectious Diseases said Tuesday.

Researchers led by NIAID researcher Andrew Redd investigated whether T cells were found in blood samples from patients recovering from the original strain of virus that recognized B.1.1.7, the variant B.1.351 originally detected in the UK was originally found in South Africa and P.1, first seen in Brazil. The NIAID is part of the National Institutes of Health, which published the study.

Each of the three variants the scientists examined contained mutations in what is known as the spike protein, which the virus uses to enter human cells. Mutations in this spike protein region could make it less noticeable to T cells and neutralizing antibodies, another important part of the immune response, after infection or vaccination, the researchers said.

In the study, which used blood samples from 30 recovered Covid-19 patients, T-cell responses “remained largely intact and were able to detect virtually all mutations in the variants studied,” they said, adding that even larger studies are required.

“The researchers note that their results suggest that the T-cell response in convalescents, and most likely in vaccines, is largely unaffected by the mutations found in these three variants and should provide protection against emerging variants,” the US wrote Authority a press release.

The results of the study could give hope to public health officials as they attempt to vaccinate the US and other parts of the world. New variants have been a problem for health officials as studies have shown that variants can reduce the effectiveness of current vaccines. The Chief Medical Officer of the White House, Dr. Anthony Fauci, urged Americans to get vaccinated as soon as possible before potentially more dangerous variants emerge.

On Monday, the head of the Centers for Disease Control and Prevention, Dr. Rochelle Walensky, the reporter. She said she was concerned the nation was facing “impending doom” as variants spread and daily Covid-19 cases rise again, threatening to send more people to the hospital.

Scientists say strong responses from both antibodies and T cells are likely required for an effective immune response against the virus. Further studies to examine immune responses are still needed, the researchers stressed, including whether a booster shot would be effective against emerging variants.

“New variants continue to be identified around the world and it will be important to continuously monitor them for possible accumulation of T cell escape mutations,” the researchers wrote.

The researchers also noted that the study had limitations, including the relatively small size of the population studied and that all participants were from North America.